AskBio, a rapidly growing Triangle gene therapy company that earlier this year raised $235 million from investors, is adding nanotechnology to its arsenal of products and services.
Read More
Pfizer’s announcement Wednesday that it will invest $500 million and add 300 jobs at its facilities in Sanford symbolizes the Triangle region’s growing prominence as a center for gene therapy research and development. Jim Shamp, director of public relations at the North Carolina Biotechnology Center, takes a look at the gene therapy-Triangle boom.
Read More
Emboldened by a recent cash infusion of $225 million from investors, AskBio, a clinical stage gene therapy company in Research Triangle Park, has acquired a Scottish company to help it develop therapeutics for a wider array of genetic disorders than the rare diseases it has targeted to date.
Read More
The potential for gene therapy to actually cure debilitating and deadly genetic disorders got another window opened today with a collaboration between two cutting-edge companies from North Carolina and the Boston area.
Read More
RESEARCH TRIANGLE PARK – Led by 10 deals made in the Triangle, startups raised more than $337 million in the second quarter, the lowest total in three years, according to a new report from Dow Jones VemtureSource. But there are caveats. To keep things in perspective, 2018 and 2017 represented...
Read More
Asklepios BioPharmaceutical (AskBio), a gene therapy platform company based in Chapel Hill, has spun out its fourth company, Actus Therapeutics, to develop gene therapies for rare genetic diseases.
Read More
